Purilex® compacted (cephalexin monohydrate)

Purilex® compacted (cephalexin monohydrate)
Product Description

Centrient Pharmaceuticals provides wide range of semi-synthetic cephalosporins which includes purilex® compacted (cephalexin monohydrate). Characteristics: granules obtained by means of dry compaction of the crystalline powder without adding any excipients. Granules are produced using green enzymatic technology in a sustainable and environmentally friendly manner. No solvents are used in the process leading to improved smell of the product, with the exception of acetone used for the final product wash. Application: the product is suitable for the manufacture of capsules after the addition of excipients such as magnesium stearate. Therapeutic category: oral, broad spectrum cephalosporin. Appearance: white- almost white powder with granules. Shelf-life: minimum 4 years (prod. Dsp spain) or 3 years (prod. Dsp china) in the original packaging under 'storage conditions'. Storage conditions: below 25 ºc, protected from light and moisture. Packaging & shipping: product is packed in 25 kg in a pe bag, which is placed inside a sealed aluminum, pe coated, bag; outer packaging is a cardboard box. Contact us for more information.

Centrient Pharmaceuticals

  • NL
  • 2015
    On CPHI since
  • 3
    Certificates
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator
Primary activities
Finished Formulation products Distributor/Buyer
Generic APIs producer
Specifications
  • Selling Points
    Packaging; Quality Service
  • Supplied from
    Netherlands

Centrient Pharmaceuticals

  • NL
  • 2015
    On CPHI since
  • 3
    Certificates
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator
Primary activities
Finished Formulation products Distributor/Buyer
Generic APIs producer

More Products from Centrient Pharmaceuticals (94)

Centrient Pharmaceuticals resources (2)

  • News Centrient Pharmaceuticals announces completion of acquisition of Astral SteriTech

    Centrient Pharmaceuticals (“Centrient”), the business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins and anti-fungals, today announced the completion of the acquisition of Astral SteriTech Private Limited (“Astral SteriTech”).

    With the addition of Astral SteriTech’s Semi-Synthetic Cephalosporin and Semi-Synthetic Penicillin sterile injectable finished dosage forms to Centrient’s product portfolio, the company can now further meet the needs of customers and reach more patients with its critical life-saving medicine.

  • Technical Data Overview Available MAs

    Available Marketing Authorizations